Sign in
Taking peopleNo phase

Rivaroxaban plus aspirin after iliac vein stenting for deep vein thrombosis

Tests rivaroxaban with aspirin after vein stenting in people with leg clots.

Key facts

Who runs it
First Affiliated Hospital of Zhejiang University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Status
Recruiting
People taking part
172 people, planned
Started
3 Nov 2021
Expected to end
30 Jun 2027
Type of study
Interventional
Treatments tested
  • Rivaroxaban
  • Aspirin
Record updated
25 September 2025

Who can take part

The trial is looking for adults with a recent deep vein clot (DVT) and a narrowed iliac vein in the pelvis on the same side. They must have had the clot removed with a catheter and a stent placed in the iliac vein.

Age
18 years and older
Sex
All
Disease stage
Acute DVT that started no more than 3 weeks ago and reaches the thigh or pelvic veins. The iliac vein on the same side is narrowed by more than 50%. The narrowing comes from vein compression (Cockett syndrome) or clot left after removal.
Earlier treatment
Must have had percutaneous mechanic thrombectomy (PMT), a catheter procedure to remove the clot, with or without catheter directed thrombolysis (CDT). Must have had an iliac vein stent placed within 30 days of PMT or CDT. Cannot join if already taking blood thinners or antiplatelet drugs for other diseases before the DVT.
Main reasons for not taking part
  • Long-standing (chronic) DVT, or DVT that started more than 3 weeks ago, or a clot only in the lower leg
  • Glomerular filtration rate (kidney function) below 60ml/min
  • Varicose veins or poor vein function in the same leg before the DVT
  • Heart attack in the past 6 months, or artery blockage, narrowing, aneurysm or tear in the belly or leg arteries
  • High bleeding risk, or unable to take antiplatelet drugs or anticoagulants
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • IC1. Subjects who were diagnosed with deep venous thrombus (DVT) with ipsilateral iliac venous stenosis (>50%). The ipsilateral iliac venous stenosis can be caused either by iliac vein compression (i.e. Cockett syndrome) or residue iliac venous thrombus after percutaneous mechanic thrombectomy
  • IC2. Subjects who accepted percutaneous mechanic thrombectomy (PMT) to decrease the burden of thrombus, with or without catheter directed thrombolysis (CDT)
  • IC3. Subjects who accepted iliac venous stent(s) implantation during the perioperative period of PMT or CDT (≤30 days post PMT or CDT)

Who cannot take part

  • EC3. Subject has glomerular filtration rate < 60ml/min. EC4. Subject has ipsilateral varicose vein or suffers from ipsilateral venous insufficiency prior to the DVT. The manifestations of venous insufficiency include skin pigmentation, edema, lipodermatosclerosis and venous ulcer
  • EC9. Subject has been taking anticoagulants or antiplatelet drugs for other diseases prior to the DVT
  • EC7. Subject has contraindication to antiplatelet drugs or anticoagulants. EC8. Subject has systemic disease(s) that cannot be treated by current medicine
  • Subject who has at least one of the below conditions will be considered at high bleeding risk: Primary history of intracerebral haemorrhage or ischemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR <15ml/min/1.73 m2
  • EC10. Subject less than 18 years old or rejected to join this study. EC11. Subject has myocardial infarction during the past 6 months. EC12. EC12. Subject who is at high bleeding risk*
  • EC1. Subject has chronic DVT or the onset of DVT is longer than 3 weeks, or chronic DVT
  • EC2. Subject has isolated distal DVT, which does not affect ipsilateral femoral or iliac vein
  • EC5. Subject has acute arterial embolism on either side or suffers from known moderate or greater stenosis at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery
  • EC6. Subject has known aneurysm(s) or current limiting dissection at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.

The group in the trial

  • Anticoagulant plus antiplatelet therapyTreatment being tested

    For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.

    Treatment: Rivaroxaban and Aspirin

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Plain-language title
Rivaroxaban plus aspirin after iliac vein stenting for deep vein thrombosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT04694248, who can take part
Record updated
25 September 2025